Please try another search
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer’s diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Sylvie L. Gregoire | 63 | 2023 | Co-Founder & Director |
Robert J. Cobuzzi | 59 | 2023 | COO & Director |
John J. Alam | 62 | 2023 | Co-Founder, CEO, President & Director |
Jeffrey V. Poulton | 56 | 2023 | Independent Director |
Jane Holmes Hollingsworth | 65 | 2020 | Independent Director |
Frank E. Zavrl | 58 | 2023 | Independent Director |
Marwan Noel Sabbagh | 58 | 2023 | Independent Non-Executive Director |
Joshua S. Boger | 73 | 2024 | Independent Chair of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review